drugset / Trial / NCT00234390

PreAsthmaControl (PAC)

NCT00234390 ↗

Phase 4 Completed 400 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate the ability of budesonide, given during episodes of troublesome lung symptoms to reduce further symptoms in infants and young children at risk of developing asthma

Timeline

Start
1998-11
Primary completion
—
Completion
2004-12

Outcome

Missed primary endpoint

paper absolute difference, 1 percent; 95 percent confidence interval, -4.8 to 6.9 percent). PMID 16687712 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 400 ug Inhaled

Indications